Research & Development
Unity biotechnology Appoints David L. Lacey, M.D. to Board of Directors
12 February 2018 - - US-based age-related afflictions treatment developer Unity biotechnology, Inc. has named David L. Lacey, M.D. to its board of directors, the company said.
Lacey brings more than 30 years of experience in medical research to Unity, including a 17-year tenure at Amgen leading research across multiple disease areas.
Lacey concluded his tenure at Amgen as senior vice president and head of discovery research, leading more than 1,200 scientists in a multi-site research organization covering four broad therapeutic areas, including oncology, inflammation, metabolic disorders, and neuroscience.
He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway that resulted in the therapeutics Prolia for osteoporosis, and Xgeva for cancer-related bone diseases.
Following his retirement from Amgen in 2011, Lacey has advised multiple companies and venture capitalists in the biopharmaceutical industry.
He currently serves on the board of directors for Inbiomotion SL, Atreca, and Nurix, Inc.
Lacey received a bachelor's degree in biology and medical doctorate from the University of Colorado and is board certified in anatomical pathology.
Privately held Unity biotechnology is developing therapeutics that increase health span by preventing, halting, or reversing diseases of aging.
The company's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions such as osteoarthritis, atherosclerosis, eye diseases, and kidney disease.
Its management team has collectively moved more than 90 therapeutic candidates into human clinical trials and developed 13 FDA-approved medicines.